Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world in JHEP Reports

2025
ASL Asti
ASL Biella

Tipo pubblicazione

Article

Autori/Collaboratori (104)Vedi tutti...

Terracciani F
Unit of Clinical Medicine and Hepatology, Fondazione Policlinico Universitario Campus Bio-medico di Roma, Italy
De Vincentis A
Unit of Internal Medicine, Fondazione Policlinico Universitario Campus Bio-medico di Roma, Italy
D'Amato D
Gastroenterology Unit, Città della Salute e della Scienza University Hospital, Turin, Italy

et alii...

Abstract

Background & Aims: Several studies have assessed the short-term effectiveness and safety of obeticholic acid (OCA) in the real-world setting. We aimed to extend knowledge on the real-world effectiveness and safety of OCA treatment by expanding sample size and follow-up, and by exploring changes in liver stiffness measurement (LSM) over time. Methods: The RECAPITULATE project involves centres belonging to the “Italian PBC registry” and/or the “Club Epatologi Ospedalieri” PBC working group. Effectiveness was evaluated as biochemical response according to POISE and normal range (NR) criteria (normal alkaline phosphatase/alanine aminotransferase/bilirubin). Safety was assessed as the incidence of de novo/worsening pruritus and discontinuation rate/causes. Available LSMs were also captured. Results: We included 747 patients from 66 Italian centres: mean age 58 years; female/male 88%/14%; median follow-up 24 months [IQR 12-42]; 28% with cirrhosis, and 14% with autoimmune hepatitis (AIH)/PBC overlap syndrome. Probabilities of POISE and NR response increased from baseline to 57% and 20%, respectively, by the 42nd month. The probabilities of response were lower in patients with cirrhosis (p = 0.02 and p = 0.004 for POISE and NR), but not different between patients with AIH/PBC and pure PBC (p = 0.8). Overall, 130 patients (17%) discontinued treatment, mainly due to pruritus (36.9%), while 28.5% did so after developing hepatic events. The discontinuation rate was higher in patients with cirrhosis (p <0.001). LSM was available in 573 patients (?77%), of whom 255 had multiple measurements. LSM variation over time differed based on the attainment of POISE biochemical response (expected mean annual variation -0.48 [-0.78, -0.19] in responders vs. +0.33 [-0.07, 0.73] in non-responders, respectively, p <0.001). Conclusions: Our findings confirm the effectiveness and safety profiles of OCA in the medium/long term and demonstrate that biochemical response is associat

Il documento è reperibile nella banca dati EMBASE.
Se sei accreditato in BVS-P effettua l'accesso per utilizzare i nostri servizi.

DOI : 10.1016/j.jhepr.2025.101448

Keywords

alanine aminotransferase; alkaline phosphatase; bilirubin; obeticholic acid; adult; age; article; ascites; autoimmune hepatitis; biochemistry; cohort analysis; controlled study; decompensated liver cirrhosis; drug dose titration; drug efficacy; drug safety; drug withdrawal; dynamics; esophagus hemorrhage; female; follow up; hepatic encephalopathy; human; hypertransaminasemia; incidence; information processing; Italian (citizen); Italy; jaundice; liver cirrhosis; liver stiffness; long term care; major clinical study; male; observational study; primary biliary cirrhosis; probability; pruritus; real world data; retrospective study; sex; stomach hemorrhage; treatment response;